Diuretic Comparison Project

NCT ID: NCT02185417

Last Updated: 2024-05-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

20723 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-15

Study Completion Date

2022-12-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Diuretic Comparison Project aimed to evaluate whether chlorthalidone, as compared with hydrochlorothiazide, would reduce the risk of major nonfatal cardiovascular disease outcomes and non-cancer-related deaths in older patients with hypertension who were receiving hydrochlorothiazide at baseline. The investigators incorporated the pragmatic methods used by the Department of Veterans Affairs (VA) Healthcare System to provide a real-world assessment of the effectiveness of chlorthalidone as compared with hydrochlorothiazide in routine clinical care.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Thiazide-type diuretics have been in use for more than 50 years and are considered as the first-line treatment for hypertension. Of the more than 1 million Veterans prescribed a thiazide-type diuretic each year, more than 95% receive hydrochlorothiazide, and fewer than 2.5% receive chlorthalidone. However, indirect evidence has been accumulating for many years that chlorthalidone may be more effective than hydrochlorothiazide at preventing cardiovascular events.

The Diuretic Comparison Project was conducted with a clinically integrated design (termed a "point of care" or "pragmatic embedded" trial). The key feature of our design was that, instead of employing local investigators, the investigators developed centralized trial procedures and implemented into the VA electronic health record (EHR) and healthcare delivery systems. This approach enabled us to conduct trial-related interactions and randomization with the use of data in the EHRs, centralize recruitment efforts without the use of site staff, eliminate the need for trial-related visits and procedures, and centralize data capture from administrative databases.

This study was performed to answer a question of whether chlorthalidone is more effective than hydrochlorothiazide at preventing cardiovascular outcomes. Consent was obtained from eligible participants who were willing to participate and their primary care providers. With provider assented to the patient undergoing randomization, 3,523 older patients with hypertension were randomized across 72 VA health care systems. Patients across the US (including Puerto Rico and District of Columbia) were enrolled. Participants were randomly assigned to continue with existing hydrochlorothiazide treatment regimen (25/50mg daily) or switch to a dose equivalent chlorthalidone (12.5/25 mg daily).

The primary outcome was the first occurrence of a composite outcome consisting of a nonfatal cardiovascular event or non-cancer related death. Nonfatal cardiovascular events included nonfatal myocardial infarction, stroke, hospitalization for heart failure, or urgent coronary revascularization for unstable angina.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hydrochlorothiazide

Participants remained on the existing hydrochlorothiazide treatment regimen (a daily dose of 25 or 50 mg).

Group Type ACTIVE_COMPARATOR

Hydrochlorothiazide (HCTZ)

Intervention Type DRUG

Trial activities following study randomization were considered as usual care. Prescriptions of the allocated drug were managed by the primary care providers and patients would receive the prescribed mediations through the VA outpatient pharmacy services.

Chlorthalidone

Participants switched to an equivalent dose of chlorthalidone (a daily dose of 12.5 or 25 mg).

Group Type ACTIVE_COMPARATOR

Chlorthalidone (CTD)

Intervention Type DRUG

Trial activities following study randomization were considered as usual care. Prescriptions of the allocated drug were managed by the primary care providers and patients would receive the prescribed mediations through the VA outpatient pharmacy services.

Providers

Providers were enrolled in order to contact their potentially eligible patients and were not included in the results

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hydrochlorothiazide (HCTZ)

Trial activities following study randomization were considered as usual care. Prescriptions of the allocated drug were managed by the primary care providers and patients would receive the prescribed mediations through the VA outpatient pharmacy services.

Intervention Type DRUG

Chlorthalidone (CTD)

Trial activities following study randomization were considered as usual care. Prescriptions of the allocated drug were managed by the primary care providers and patients would receive the prescribed mediations through the VA outpatient pharmacy services.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

HCTZ CTD

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* over age 65 years
* receiving hydrochlorothiazide from the VA pharmacy at a daily dose of 25 or 50 mg
* most recent SBP ≥120 mm Hg and no records of SBP \<120 mm Hg in the past 90 days

Exclusion Criteria

* impaired decision-making capacity rendering the patient unable to provide informed consent (i.e., if there is any question during the nurse's EHR chart review that the individual does not have the ability to make an autonomous decision or the PCP declines permission to randomize)
* death expected within 6 months (inferred by PCP permission to randomize)
* blood potassium level \<3.1 or 3.5 (if taking digoxin) meq/L in the past 90 days
* blood sodium level \<130 meq/L in the past 90 days
* enrolled in Medicare Part C (This exclusion only applied if there might be insufficient EHR data available to the study team)
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

VA Office of Research and Development

FED

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Areef Ishani, MD MS

Role: STUDY_CHAIR

Minneapolis VA Health Care System, Minneapolis, MN

William C Cushman, MD

Role: STUDY_CHAIR

Memphis VA Medical Center, Memphis, TN

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Birmingham VA Medical Center, Birmingham, AL

Birmingham, Alabama, United States

Site Status

Alaska VA Healthcare System, Anchorage, AK

Anchorage, Alaska, United States

Site Status

Veterans Health Care System of the Ozarks, Fayetteville, AR

Fayetteville, Arkansas, United States

Site Status

Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR

Little Rock, Arkansas, United States

Site Status

VA Central California Health Care System, Fresno, CA

Fresno, California, United States

Site Status

VA Long Beach Healthcare System, Long Beach, CA

Long Beach, California, United States

Site Status

VA Palo Alto Health Care System, Palo Alto, CA

Palo Alto, California, United States

Site Status

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

West Los Angeles, California, United States

Site Status

Rocky Mountain Regional VA Medical Center, Aurora, CO

Aurora, Colorado, United States

Site Status

Grand Junction VA Medical Center, Grand Junction, CO

Grand Junction, Colorado, United States

Site Status

VA Connecticut Healthcare System West Haven Campus, West Haven, CT

West Haven, Connecticut, United States

Site Status

Wilmington VA Medical Center, Wilmington, DE

Wilmington, Delaware, United States

Site Status

Washington DC VA Medical Center, Washington, DC

Washington D.C., District of Columbia, United States

Site Status

Bay Pines VA Healthcare System, Pay Pines, FL

Bay Pines, Florida, United States

Site Status

North Florida/South Georgia Veterans Health System, Gainesville, FL

Gainesville, Florida, United States

Site Status

VA Pacific Islands Health Care System, Honolulu, HI

Honolulu, Hawaii, United States

Site Status

Boise VA Medical Center, Boise, ID

Boise, Idaho, United States

Site Status

VA Illiana Health Care System, Danville, IL

Danville, Illinois, United States

Site Status

Edward Hines Jr. VA Hospital, Hines, IL

Hines, Illinois, United States

Site Status

Captain James A. Lovell Federal Health Care Center, North Chicago, IL

North Chicago, Illinois, United States

Site Status

Richard L. Roudebush VA Medical Center, Indianapolis, IN

Indianapolis, Indiana, United States

Site Status

VA Central Iowa Health Care System, Des Moines, IA

Des Moines, Iowa, United States

Site Status

Iowa City VA Health Care System, Iowa City, IA

Iowa City, Iowa, United States

Site Status

Maine VA Medical Center, Augusta, ME

Togus, Maine, United States

Site Status

Rehabilitation R&D Service, Baltimore, MD

Baltimore, Maryland, United States

Site Status

Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA

Bedford, Massachusetts, United States

Site Status

VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

Boston, Massachusetts, United States

Site Status

Aleda E. Lutz VA Medical Center, Saginaw, MI

Saginaw, Michigan, United States

Site Status

Minneapolis VA Health Care System, Minneapolis, MN

Minneapolis, Minnesota, United States

Site Status

Minneapolis VA Health Care System, Minneapolis, MN

Minneapolis, Minnesota, United States

Site Status

St. Cloud VA Health Care System, St. Cloud, MN

Saint Cloud, Minnesota, United States

Site Status

VA Gulf Coast Veterans Health Care System, Biloxi, MS

Biloxi, Mississippi, United States

Site Status

Kansas City VA Medical Center, Kansas City, MO

Kansas City, Missouri, United States

Site Status

St. Louis VA Medical Center John Cochran Division, St. Louis, MO

St Louis, Missouri, United States

Site Status

Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE

Omaha, Nebraska, United States

Site Status

Manchester VA Medical Center, Manchester, NH

Manchester, New Hampshire, United States

Site Status

New Mexico VA Health Care System, Albuquerque, NM

Albuquerque, New Mexico, United States

Site Status

Albany VA Medical Center Samuel S. Stratton, Albany, NY

Albany, New York, United States

Site Status

Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY

New York, New York, United States

Site Status

Syracuse VA Medical Center, Syracuse, NY

Syracuse, New York, United States

Site Status

Durham VA Medical Center, Durham, NC

Durham, North Carolina, United States

Site Status

Fargo VA Healthcare System, Fargo, ND

Fargo, North Dakota, United States

Site Status

Cincinnati VA Medical Center, Cincinnati, OH

Cincinnati, Ohio, United States

Site Status

Louis Stokes VA Medical Center, Cleveland, OH

Cleveland, Ohio, United States

Site Status

Dayton VA Medical Center, Dayton, OH

Dayton, Ohio, United States

Site Status

Jackson C. Montgomery VA Medical Center, Muskogee, OK

Muskogee, Oklahoma, United States

Site Status

VA Portland Health Care System, Portland, OR

Portland, Oregon, United States

Site Status

VA Roseburg Healthcare System, Roseburg, OR

Roseburg, Oregon, United States

Site Status

VA Southern Oregon Rehabilitation Center and Clinics, White City, OR

White City, Oregon, United States

Site Status

Coatesville VA Medical Center, Coatesville, PA

Coatesville, Pennsylvania, United States

Site Status

Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

Philadelphia, Pennsylvania, United States

Site Status

VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA

Pittsburgh, Pennsylvania, United States

Site Status

Wilkes-Barre VA Medical Center, Wilkes-Barre, PA

Wilkes-Barre, Pennsylvania, United States

Site Status

Ralph H. Johnson VA Medical Center, Charleston, SC

Charleston, South Carolina, United States

Site Status

Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC

Columbia, South Carolina, United States

Site Status

VA Black Hills Health Care System Fort Meade Campus, Fort Meade, SD

Sturgis, South Dakota, United States

Site Status

Memphis VA Medical Center, Memphis, TN

Memphis, Tennessee, United States

Site Status

Memphis VA Medical Center, Memphis, TN

Memphis, Tennessee, United States

Site Status

Tennessee Valley Healthcare System Nashville Campus, Nashville, TN

Nashville, Tennessee, United States

Site Status

VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX

Dallas, Texas, United States

Site Status

Michael E. DeBakey VA Medical Center, Houston, TX

Houston, Texas, United States

Site Status

South Texas Health Care System, San Antonio, TX

San Antonio, Texas, United States

Site Status

White River Junction VA Medical Center, White River Junction, VT

White River Junction, Vermont, United States

Site Status

Hampton VA Medical Center, Hampton, VA

Hampton, Virginia, United States

Site Status

Huntington VA Medical Center, Huntington, WV

Huntington, West Virginia, United States

Site Status

William S. Middleton Memorial Veterans Hospital, Madison, WI

Madison, Wisconsin, United States

Site Status

Clement J. Zablocki VA Medical Center, Milwaukee, WI

Milwaukee, Wisconsin, United States

Site Status

Tomah VA Medical Center, Tomah, WI

Tomah, Wisconsin, United States

Site Status

Sheridan VA Medical Center, Sheridan, WY

Sheridan, Wyoming, United States

Site Status

VA Caribbean Healthcare System, San Juan, PR

San Juan, , Puerto Rico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Puerto Rico

References

Explore related publications, articles, or registry entries linked to this study.

Ishani A, Leatherman SM, Woods P, Hau C, Klint A, Lew RA, Taylor AA, Glassman PA, Brophy MT, Fiore LD, Ferguson RE, Cushman WC. Design of a pragmatic clinical trial embedded in the Electronic Health Record: The VA's Diuretic Comparison Project. Contemp Clin Trials. 2022 May;116:106754. doi: 10.1016/j.cct.2022.106754. Epub 2022 Apr 4.

Reference Type BACKGROUND
PMID: 35390512 (View on PubMed)

Ferguson RE, Leatherman SM, Woods P, Hau C, Lew R, Cushman WC, Brophy MT, Fiore L, Ishani A. Practical issues in pragmatic trials: the implementation of the Diuretic Comparison Project. Clin Trials. 2023 Jun;20(3):276-283. doi: 10.1177/17407745231160553. Epub 2023 Mar 29.

Reference Type BACKGROUND
PMID: 36992530 (View on PubMed)

Ishani A, Cushman WC, Leatherman SM, Lew RA, Woods P, Glassman PA, Taylor AA, Hau C, Klint A, Huang GD, Brophy MT, Fiore LD, Ferguson RE; Diuretic Comparison Project Writing Group. Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. N Engl J Med. 2022 Dec 29;387(26):2401-2410. doi: 10.1056/NEJMoa2212270. Epub 2022 Dec 14.

Reference Type RESULT
PMID: 36516076 (View on PubMed)

Hau C, Efird JT, Leatherman SM, Soloviev OV, Glassman PA, Woods PA, Ishani A, Cushman WC, Ferguson RE. A Centralized EHR-Based Model for the Recruitment of Rural and Lower Socioeconomic Participants in Pragmatic Trials: A Secondary Analysis of the Diuretic Comparison Project. JAMA Netw Open. 2023 Sep 5;6(9):e2332049. doi: 10.1001/jamanetworkopen.2023.32049.

Reference Type RESULT
PMID: 37656456 (View on PubMed)

Leatherman SM, Beaudette-Zlatanova B, Robben G, Glassman PA, Woods P, Ferguson RE, Cushman WC, Ishani A. Provider experiences with and attitudes about an embedded pragmatic clinical trial. BMC Prim Care. 2025 Apr 23;26(1):121. doi: 10.1186/s12875-025-02799-w.

Reference Type DERIVED
PMID: 40269774 (View on PubMed)

Ishani A, Hau C, Raju S, Wise JK, Glassman PA, Taylor AA, Ferguson RE, Cushman WC, Leatherman SM. Chlorthalidone vs Hydrochlorothiazide and Kidney Outcomes in Patients With Hypertension: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 Dec 2;7(12):e2449576. doi: 10.1001/jamanetworkopen.2024.49576.

Reference Type DERIVED
PMID: 39656458 (View on PubMed)

Ishani A, Hau C, Cushman WC, Leatherman SM, Lew RA, Glassman PA, Taylor AA, Ferguson RE. Chlorthalidone vs Hydrochlorothiazide for Hypertension Treatment After Myocardial Infarction or Stroke: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 May 1;7(5):e2411081. doi: 10.1001/jamanetworkopen.2024.11081.

Reference Type DERIVED
PMID: 38743423 (View on PubMed)

Klint AL, Leatherman SM, Taylor O, Glassman PA, Ferguson RE, Cushman WC, Ishani A. Telephone informed consent in a pragmatic point-of-care clinical trial embedded in primary care. Contemp Clin Trials. 2023 Aug;131:107239. doi: 10.1016/j.cct.2023.107239. Epub 2023 May 25.

Reference Type DERIVED
PMID: 37244366 (View on PubMed)

Raju S, Hau C, Woods P, Flynn M, Sadatis C, McPherson J, Tella A, Ishani A, Ferguson RE, Leatherman SM. Ascertainment of stroke from administrative data to support a pragmatic embedded clinical trial. Contemp Clin Trials. 2023 Jul;130:107214. doi: 10.1016/j.cct.2023.107214. Epub 2023 May 1.

Reference Type DERIVED
PMID: 37137378 (View on PubMed)

Leatherman SM, Hau C, Klint A, Glassman PA, Taylor AA, Ferguson RE, Cushman WC, Ishani A. The impact of COVID-19 on a large pragmatic clinical trial embedded in primary care. Contemp Clin Trials. 2023 Jun;129:107179. doi: 10.1016/j.cct.2023.107179. Epub 2023 Apr 7.

Reference Type DERIVED
PMID: 37031794 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

597

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Chlorthalidone in Chronic Kidney Disease
NCT02841280 COMPLETED PHASE2
Aldosterone Blockade in Heart Failure
NCT00523757 COMPLETED PHASE3